The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Open accessAbstract
TGR5 is a G protein-coupled receptor expressed in brown adipose tissue and muscle, where its activation by bile acids triggers an increase in energy expenditure and attenuates diet-induced obesity. Using a combination of pharmacological and genetic gain- and loss-of-function studies in vivo, we show here that TGR5 signaling induces intestinal glucagon-like peptide-1 (GLP-1) release, leading to improved liver and pancreatic function and enhanced glucose tolerance in obese mice. In addition, we show that the induction of GLP-1 release in enteroendocrine cells by 6alpha-ethyl-23(S)-methyl-cholic acid (EMCA, INT-777), a specific TGR5 agonist, is linked to an increase of the intracellular ATP/ADP ratio and a subsequent rise in intracellular calcium mobilization. Altogether, these data show that the TGR5 signaling pathway is critical in regulating intestinal GLP-1 secretion in vivo, and suggest that pharmacological targeting of TGR5 may constitute a promising incretin-based strategy for the treatment of diabesity and associated metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bacteria-derived secondary bile acids (lithocholic acid, deoxycholic acid) can activate the G-protein coupled bile acid receptor Gpbar1 receptor (TGR5) in L cells, promoting the peripheral release of GLP-1 and PYY (Katsuma et al., 2005;Thomas et al., 2009;Ullmer et al., 2013).”
From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Thomas et al., 2009
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Bile acids also increase energy expenditure in brown adipose tissue, preventing obesity and resistance to insulin. This effect is dependent on induction of the type 2 iodothyronine deiodinase and is mediated by the binding of bile acids to a novel G-protein-coupled receptor TGR5 148.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [148]
In the citing paper
“Bile acids induce insulin secretion directly via the transmembrane bile acid receptor Takeda G protein–coupled receptor 5 (on β cells and indirectly via stimulation of l-cell derived GLP-1 and subsequent insulin release (110–112).”
From Metabolic Flexibility as an Adaptation to Energy Resources and Requirements in Health and Disease (2018) · cites this paper as [112]
In the citing paper
“TGR5 is therefore a new and attractive target for treating obesity, since it can theoretically protect against obesity and its complications via two distinct and potentially synergistic mechanisms: increased energy expenditure and improved insulin sensitivity 148.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [148]
In the citing paper
“Bile acids also increase energy expenditure in brown adipose tissue, preventing obesity and resistance to insulin. This effect is dependent on induction of the type 2 iodothyronine deiodinase and is mediated by the binding of bile acids to a novel G-protein-coupled receptor TGR5 148.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [148]
In the citing paper
“One promising TGR5 agonist, INT-777, has already shown efficacy in vivo, increasing energy expenditure and reducing adiposity in mice with diet-induced obesity 148,149.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [148]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
Self-citationThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
A G Protein-coupled Receptor Responsive to Bile Acids
Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M., Fukusumi, S., Habata, Y., Itoh, T., Shintani, Y., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209706200 · Cited by 1,628
Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120
Hirasawa, A., Tsumaya, K., Awaji, T., Katsuma, S., Adachi, T., Yamada, M., Sugimoto, Y., Miyazaki, S., & Tsujimoto, G. (2004) · Nature Medicine · doi:10.1038/nm1168 · Cited by 1,580
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c
渡辺, 光., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., & Auwerx, J. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21025 · Cited by 1,425
Self-citationTargeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422 · cited 2×
“The complete absence of changes in the expression level of classical target genes of FXR in the liver, such as cholesterol 7a hydroxylase (CYP7A1) and bile salt export pump (BSEP) (Thomas et al., 2008), further confirmed the specificity of INT-777 toward TGR5 (Figure S6B).”
BackgroundSelf-citationIdentification of membrane-type receptor for bile acids (M-BAR)
Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama, E., Nakamura, T., Itadani, H., & Tanaka, K. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02550-0 · Cited by 993
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506982103 · Cited by 974
Cited by
Sorted by citations
Items 401–500 of 999
Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective
Feng, H., & Chen, Y. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i33.7463 · Cited by 92
The emerging role of the small intestinal microbiota in human health and disease
Ruigrok, R. A. A. A., Weersma, R. K., & Vila, A. V. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2201155 · Cited by 101
Stimulation of incretin secreting cells
Pais, R., Gribble, F. M., & Reimann, F. M. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815618177 · Cited by 105
The gut microbiota as a mediator of metabolic benefits after bariatric surgery
Anhê, F. F., Varin, T. V., Schertzer, J. D., & Marette, A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.02.002 · Cited by 93
Cometabolism of Microbes and Host: Implications for Drug Metabolism and Drug-Induced Toxicity
Li, H., & Jia, W. P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.157 · Cited by 92
Effects of Consuming Xylitol on Gut Microbiota and Lipid Metabolism in Mice
Uebanso, T., Kano, S., Yoshimoto, A., Naito, C., Shimohata, T., Mawatari, K., & Takahashi, A. (2017) · Nutrients · doi:10.3390/nu9070756 · Cited by 100
From role of gut microbiota to microbial-based therapies in type 2-diabetes
Leylabadlo, H. E., Sanaie, S., Heravi, F. S., Ahmadian, Z., & Ghotaslou, R. (2020) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2020.104268 · Cited by 94
The Metabolic Role and Therapeutic Potential of the Microbiome
Olofsson, L. E., & Bäckhed, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac004 · Cited by 99
K-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease
Cho, Y. M., & Kieffer, T. J. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00004-7 · Cited by 98
Bile Acid Sequestrants for Lipid and Glucose Control
Staels, B., Handelsman, Y., & Fonseca, V. A. (2010) · Current Diabetes Reports · doi:10.1007/s11892-009-0087-5 · Cited by 97
Antibiotics, gut microbiome and obesity
Leong, K. S. W., Derraik, J. G. B., Hofman, P. L., & Cutfield, W. S. (2017) · Clinical Endocrinology · doi:10.1111/cen.13495 · Cited by 98
Lau, L. H. S., & Wong, S. H. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_9 · Cited by 93
Ullmer, C., Alvarez Sanchez, R., Sprecher, U., Raab, S., Mattei, P., Dehmlow, H., Sewing, S., Iglesias, A., Beauchamp, J., & Conde‐Knape, K. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12158 · Cited by 92
Pharmacology and physiology of gastrointestinal enteroendocrine cells
Mace, O. J., Tehan, B. G., & Marshall, F. H. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.155 · Cited by 93
Dutia, R., Embrey, M., O'Brien, S. A., Haeusler, R. A., Agenor, K., Homel, P., McGinty, J., Vincent, R. P., Alaghband-Zadeh, J., Staels, B., et al. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.1 · Cited by 95
Farnesoid X receptor modulators 2014-present: a patent review
Sepe, V., Distrutti, E., Fiorucci, S., & Zampella, A. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1459569 · Cited by 93
Integration of Satiety Signals by the Central Nervous System
Chambers, A. P., Sandoval, D. A., & Seeley, R. J. (2013) · Current Biology · doi:10.1016/j.cub.2013.03.020 · Cited by 98
Bile Acid Receptors and Liver Cancer
Wang, X., Fu, X., Ness, C. V., Meng, Z., Ma, X., & Huang, W. (2012) · Current Pathobiology Reports · doi:10.1007/s40139-012-0003-6 · Cited by 92
Human Gut Microbiota in Health and Alzheimer’s Disease
Szablewski, L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170908 · Cited by 96
Busnelli, M., Manzini, S., & Chiesa, G. (2019) · Nutrients · doi:10.3390/nu12010079 · Cited by 92
TGR5 Signaling in Hepatic Metabolic Health
Holter, M. M., Chirikjian, M. K., Govani, V. N., & Cummings, B. P. (2020) · Nutrients · doi:10.3390/nu12092598 · Cited by 94
A review on the antibiotic florfenicol: Occurrence, environmental fate, effects, and health risks
Guo, X., Chen, H., Tong, Y., Wu, X., Tang, C., Qin, X., Guo, J., Li, P., Wang, Z., Liu, W., et al. (2023) · Environmental Research · doi:10.1016/j.envres.2023.117934 · Cited by 93
Jensen, D. D., Godfrey, C. B., Niklas, C., Canals, M., Kočan, M., Poole, D. P., Murphy, J. E., Alemi, F., Cottrell, G. S., Korbmacher, C., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.455774 · Cited by 91
New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser
Cho, Y. M., & Kieffer, T. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1986-3 · Cited by 91
Molecular mechanisms of incretin hormone secretion
Ezcurra, M., Reimann, F. M., Gribble, F. M., & Emery, E. C. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.08.013 · Cited by 97
The microbiota-gut-brain axis: Focus on the fundamental communication pathways
Bistoletti, M., Bosi, A., Banfi, D., Giaroni, C., & Baj, A. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.08.012 · Cited by 91
Song, L., Hou, Y., Xu, D., Dai, X., Luo, J., Liu, Y., Huang, Z., Yang, M., Chen, J., Hu, Y., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.008 · Cited by 91
The functions of gut microbiota-mediated bile acid metabolism in intestinal immunity
He, Y., Shaoyong, W., Chen, Y., Li, M., Gan, Y., Sun, L., Liu, Y., Wang, Y., & Jin, M. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.05.015 · Cited by 107
Determination of bile salt critical micellization concentration on the road to drug discovery
Natalini, B., Sardella, R., Gioiello, A., Ianni, F., Michele, A. D., & Marinozzi, M. (2013) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.06.029 · Cited by 88
Self-citationAgolino, G., Pino, A., Vaccalluzzo, A., Cristofolini, M., Solieri, L., Caggia, C., & Randazzo, C. L. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106357 · Cited by 99
Integrated neural and endocrine control of gastrointestinal function
Furness, J. B. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-27592-5_16 · Cited by 87
Martoni, C. J., Labbé, A., Ganopolsky, J. G., Prakash, S., & Jones, M. L. (2015) · Gut Microbes · doi:10.1080/19490976.2015.1005474 · Cited by 87
Liu, H., Tian, R., Wang, H., Feng, S., Li, H., Xiao, Y., Luan, X., Zhang, Z., Shi, N., Niu, H., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02539-x · Cited by 88
Signaling pathways and intervention for therapy of type 2 diabetes mellitus
Cao, R. Y., Tian, H., Zhang, Y., Liu, G., Xu, H., Rao, G., Tian, Y., & Fu, X. (2023) · MedComm · doi:10.1002/mco2.283 · Cited by 98
The Effect of a Bile Acid Sequestrant on Glucose Metabolism in Subjects With Type 2 Diabetes
Smushkin, G., Sathananthan, M., Piccinini, F., Man, C. D., Law, J. H., Cobelli, C., Zinsmeister, A. R., Rizza, R. A., & Vella, A. V. (2012) · Diabetes · doi:10.2337/db12-0923 · Cited by 86
Sepe, V., Renga, B., Festa, C., D’Amore, C., Masullo, D., Cipriani, S., Leva, F. S. D., Monti, M. C., Novellino, E., Limongelli, V., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500889f · Cited by 89
Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease
Li, T., & Chiang, J. Y. L. (2020) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.09.03 · Cited by 87
Gut Dysbiosis and Immune System in Atherosclerotic Cardiovascular Disease (ACVD)
Yoo, J. Y., Sniffen, S. E., Percy, K. C. M., Chidipi, B., & Pallaval, V. B. (2022) · Microorganisms · doi:10.3390/microorganisms10010108 · Cited by 88
Jayakumar, S., & Loomba, R. S. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15314 · Cited by 87
Org, E., Mehrabian, M., & Lusis, A. J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.05.035 · Cited by 85
Human Postprandial Nutrient Metabolism and Low-Grade Inflammation: A Narrative Review
Meessen, E. C. E., Warmbrunn, M. V., Nieuwdorp, M., & Soeters, M. R. (2019) · Nutrients · doi:10.3390/nu11123000 · Cited by 95
Leveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 84
ASBT(SLC10A2): A promising target for treatment of diseases and drug discovery
Yang, N., Dong, Y., Jia, G., Fan, S., Li, S.-Z., Yang, S., & Li, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110835 · Cited by 87
The Gut Microbiome: Connecting Diet, Glucose Homeostasis, and Disease
Howard, E. J., Lam, T. K. T., & Duca, F. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042220-012821 · Cited by 90
A Metabolomics-driven Elucidation of the Anti-obesity Mechanisms of Xanthohumol
Kirkwood, J. S., Legette, L. L., Miranda, C. L., Jiang, Y., & Stevens, J. F. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445452 · Cited by 85
Gut microbiota, fatty liver disease, and hepatocellular carcinoma
Chu, H., Williams, B., & Schnabl, B. (2018) · Liver Research · doi:10.1016/j.livres.2017.11.005 · Cited by 84
Stepanov, V., Stankov, K., & Mikov, M. (2013) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2013.802805 · Cited by 85
Iizuka, K. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.029 · Cited by 85
Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids
Sansome, D. J., Xie, C., Veedfald, S., Horowitz, M., Rayner, C. K., & Wu, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13869 · Cited by 84
Barathikannan, K., Chelliah, R., Rubab, M., Daliri, E. B., Elahi, F., Kim, D.-H., Agastian, P., Oh, S.-Y., & Oh, D. H. (2019) · Microorganisms · doi:10.3390/microorganisms7100456 · Cited by 85
Ducastel, S., Touche, V., Trabelsi, M.-S., Boulinguiez, A., Butruille, L., Nawrot, M., Peschard, S., Chávez-Talavera, O., Dorchies, E., Vallez, E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56743-x · Cited by 84
Calderón, G., MCRAE, A. N., Rievaj, J., Davis, J. A., Zandvakili, I., Nord, S. L., Burton, D. B., Roberts, G. P., Reimann, F. M., Gedulin, B. R., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102759 · Cited by 83
Immunology of bile acids regulated receptors
Fiorucci, S., Marchianò, S., Urbani, G., Giorgio, C. D., Distrutti, E., Zampella, A., & Biagioli, M. (2024) · Progress in Lipid Research · doi:10.1016/j.plipres.2024.101291 · Cited by 88
Wu, T., Bound, M. J., Standfield, S., Jones, K. L., Horowitz, M., & Rayner, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3961 · Cited by 84
Cholecystectomy and risk of metabolic syndrome
Ciaula, A. D., Garruti, G., Wang, D. Q. ‐., & Portincasa, P. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.04.019 · Cited by 90
Bile Acids, Their Receptors, and the Gut Microbiota
Poland, J. C., & Flynn, C. R. (2021) · Physiology · doi:10.1152/physiol.00028.2020 · Cited by 93
Vassileva, G., Hu, W., Hoos, L. M., Tetzloff, G. G., Yang, S., Liu, L., Kang, L., Davis, H. R., Hedrick, J. A., Hong, L., et al. (2010) · Journal of Endocrinology · doi:10.1677/joe-10-0009 · Cited by 89
Probiotics for the treatment of type 2 diabetes: A review of randomized controlled trials
Tiderencel, K. A., Hutcheon, D. A., & Ziegler, J. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3213 · Cited by 82
Activation of bile acid signaling improves metabolic phenotypes in high-fat diet-induced obese mice
Pierre, J. F., Martinez, K., Ye, H., Nadimpalli, A., Morton, T. C., Yang, J., Wang, Q., Patno, N., Chang, E. B., & Yin, D. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00202.2016 · Cited by 83
Lund, M. L., Sorrentino, G., Egerod, K. L., Kroone, C., Mortensen, B., Knop, F. K., Reimann, F. M., Gribble, F. M., Drucker, D. J., de Koning, E. J. P., et al. (2020) · Diabetes · doi:10.2337/db19-0764 · Cited by 84
Self-citationBile acids and neurological disease
Hurley, M. J., Bates, R., Macnaughtan, J., & Schapira, A. H. V. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108311 · Cited by 86
Liver X Receptor α and Farnesoid X Receptor Are Major Transcriptional Regulators of OATP1B1
zu Schwabedissen, H. E. M., Böttcher, K., Chaudhry, A. S., Kroemer, H. K., Schuetz, E. G., & Kim, R. B. (2010) · Hepatology · doi:10.1002/hep.23876 · Cited by 84
Rajagopal, S., Kumar, D. P., Mahavadi, S., Bhattacharya, S., Zhou, R., Corvera, C. U., Bunnett, N. W., Grider, J. R., & Murthy, K. S. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00388.2012 · Cited by 88
Bile Acids Increase Independently From Hypocaloric Restriction After Bariatric Surgery
Jahansouz, C., Xu, H., Hertzel, A. V., Serrot, F. J., Kvalheim, N., Cole, A. J., Abraham, A. A., Luthra, G., Ewing, K., Leslie, D. B., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001552 · Cited by 84
Bile acid receptors and nonalcoholic fatty liver disease
Yuan, L. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i28.2811 · Cited by 82
Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders?
Martín‐Núñez, G. M., Cornejo-Pareja, I. M., Clemente‐Postigo, M., & Tinahones, F. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.639856 · Cited by 86
The intestinal immune system and gut barrier function in obesity and ageing
Shemtov, S. J., Emani, R., Bielska, O., Covarrubias, A. J., Verdin, E. M., Andersen, J. K., & Winer, D. A. (2022) · FEBS Journal · doi:10.1111/febs.16558 · Cited by 86
GPBAR1/TGR5 Mediates Bile Acid-Induced Cytokine Expression in Murine Kupffer Cells
Lou, G., Ma, X., Fu, X., Meng, Z., Zhang, W., Wang, Y., Ness, C. V., Yu, D. D., Xu, R., & Huang, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093567 · Cited by 84
Out, C., Groen, A. K., & Brufau, G. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834f0ef3 · Cited by 85
Bile Acid Uptake Transporters as Targets for Therapy
Slijepcevic, D., & van de Graaf, S. F. J. (2017) · Digestive Diseases · doi:10.1159/000450983 · Cited by 83
Role of bile acids in the regulation of the metabolic pathways
Taoka, H., Yokoyama, Y., Morimoto, K., Kitamura, N., Tanigaki, T., Takashina, Y., Tsubota, K., & Watanabe, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i13.260 · Cited by 80
Kim, H., & Fang, S. (2018) · Laboratory Animal Research · doi:10.5625/lar.2018.34.4.140 · Cited by 83
Wang, H., Tan, Y.-Z., Mu, R.-H., Tang, S., Liu, X., Xing, S.-Y., Long, Y., Yuan, D.-H., & Hong, H. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.11.018 · Cited by 81
Radun, R., & Trauner, M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731707 · Cited by 83
Chen, M., Zhu, J., Mu, W.-J., & Guo, L. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.023 · Cited by 84
Brown adipose tissue: a potential target in the fight against obesity and the metabolic syndrome
Poekes, L., Lanthier, N., & Leclercq, I. A. (2015) · Clinical Science · doi:10.1042/cs20150339 · Cited by 83
Mikkelsen, S. U., Allin, K. H., & Knop, F. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12637 · Cited by 85
Developments in bile salt based therapies: A critical overview
Donkers, J. M., Abbing, R. L. P. R., & van de Graaf, S. F. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.12.018 · Cited by 76
Intestinal microbial metabolites in human metabolism and type 2 diabetes
Herrema, H., & Niess, J. H. (2020) · Diabetologia · doi:10.1007/s00125-020-05268-4 · Cited by 83
What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?
Kuhre, R. E., Deacon, C. F., Holst, J. J., & Petersen, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694284 · Cited by 86
Briere, D. A., Ruan, X., Cheng, C., Siesky, A. M., Fitch, T. E., Dominguez, C., Sanfeliciano, S. G., Montero, C., Suen, C. S., Xu, Y., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136873 · Cited by 80
Wu, Y., Aquino, C. J., Cowan, D. J., Anderson, D. L., Ambroso, J. L., Bishop, M. J., Boros, E. E., Chen, L., Cunningham, A., Dobbins, R. L., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400459m · Cited by 79
Specific bile acids inhibit hepatic fatty acid uptake in mice
Nie, B., Park, H. M., Kazantzis, M., Lin, M., Henkin, A. H., Ng, S. M., Song, S., Chen, Y., Tran, H., Lai, R., et al. (2012) · Hepatology · doi:10.1002/hep.25797 · Cited by 79
Bariatric surgeries: beyond restriction and malabsorption
Sandoval, D. A. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.148 · Cited by 79
Sankoda, A., Harada, N., Iwasaki, K., Yamane, S., Murata, Y., Shibue, K., Thewjitcharoen, Y., Suzuki, K., Harada, T., Kanemaru, Y., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00090 · Cited by 81
Current and Future Drug Targets in Weight Management
Witkamp, R. F. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0341-1 · Cited by 81
Wang, J., Zhang, J., Lin, X., Wang, Y., Wu, X. Y., Yang, F., Gao, W. D., Zhang, Y., Sun, J., Jiang, C., et al. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.10.014 · Cited by 77
Choucair, I., Nemet, I., Li, L., Cole, M. A., Skye, S. M., Kirsop, J. D., Fischbach, M. A., Gogonea, V., Brown, J. M., Tang, W. H. W., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000311 · Cited by 77
Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD
Jiang, X., Zheng, J., Zhang, S., Wang, B., Wu, C., & Guo, X. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00361 · Cited by 80
Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
Mori, H., Svegliati‐Baroni, G., Marzioni, M., Nicola, F. D., Santori, P., Maroni, L., Abenavoli, L., & Scarpellini, E. (2022) · Metabolites · doi:10.3390/metabo12070647 · Cited by 82
Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development
Li, T., & Chiang, J. Y. L. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000978 · Cited by 85
Role of Bile Acids in Bariatric Surgery
Wang, W., Cheng, Z., Wang, Y., Dai, Y., Zhang, X., & Hu, S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00374 · Cited by 80
Hodge, R. J., Lin, J., Johnson, L. S. V., Gould, E. P., Bowers, G. D., Nunez, D. J., & on behalf of the SB‐756050 Project Team (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.34 · Cited by 78
Sonne, D. P., Hansen, M., & Knop, F. K. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0154 · Cited by 75
Han, L., Fan, Y., Mu, N.-N., Gao, S., Li, F., Ji, X., Dou, C., & Wang, K. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.6745 · Cited by 77
Regulation of bile acid receptor activity
Wan, Y. Y., & Sheng, L. (2018) · Liver Research · doi:10.1016/j.livres.2018.09.008 · Cited by 75
The human gut microbiota and its interactive connections to diet
Milani, C., Ferrario, C., Turroni, F., Duranti, S., Mangifesta, M., van Sinderen, D., & Ventura, M. (2016) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12371 · Cited by 76
Martemucci, G., Fracchiolla, G., Muraglia, M., Tardugno, R., Dibenedetto, R. S., & D‘Alessandro, A. G. (2023) · Antioxidants · doi:10.3390/antiox12122091 · Cited by 89
The intersection of nonalcoholic fatty liver disease and obesity
Baidal, J. W., & Lavine, J. E. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8390 · Cited by 75
Effects of oral florfenicol and azithromycin on gut microbiota and adipogenesis in mice
Li, R., Wang, H., Shi, Q., Wang, N., Zhang, Z., Xiong, C., Liu, J., Chen, Y., Jiang, L., & Jiang, Q. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181690 · Cited by 74
Metadata
- Authors
- Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., Pellicciari, R., Auwerx, J., & Schoonjans, K.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- University of Perugia (IT)
- Intercept Pharmaceuticals (United States) (US)
- Corresponding author
- Auwerx, Johan
- Schoonjans, Kristina
- ORCID
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 10
- Issue
- 3
- Pages
- 167-177
- ISSN
- 1550-4131 (ISSN-L)
- PMC
- PMC2739652
- OpenAlex
- W2081271380
- Cited by
- 1,885
- References
- 43
- Citations by year
- 2026: 143 · 2025: 100 · 2024: 153 · 2023: 112 · 2022: 135 · 2021: 141 · 2020: 148 · 2019: 113 · 2018: 124 · 2017: 126 · 2016: 106 · 2015: 108 · 2014: 87 · 2013: 91 · 2012: 69
- FWCI
- 47.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1415 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell Metabolism (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- European Commission
- Centre National de la Recherche Scientifique
- Australian Research Council
- National Institutes of Health
- Agence Nationale de la Recherche
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Nursing › Nutrition and Dietetics › Biochemical Analysis and Sensing Techniques
- Keywords
- TGR5, glucose homeostasis, glucagon-like peptide-1, enteroendocrine cells, energy expenditure, diet-induced obesity, diabesity, ATP/ADP ratio, calcium mobilization, brown adipose tissue, pancreatic function, liver function, TGR5 agonists, INT-777, incretin-based therapy
- MeSH terms
- Adenosine Triphosphate, Animals, Bile Acids and Salts, Calcium, Cell Line, Cholic Acids, Cricetulus, Glucose, Cricetinae, Homeostasis, Humans, Insulin, Male, Mice, Inbred C57BL, Mice, Obese, Oxidative Phosphorylation, Signal Transduction, CHO Cells, Mice, Knockout, Enteroendocrine Cells, Receptors, G-Protein-Coupled, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
